経口効果のあるCVS-1123は,意識のある犬の冠動脈栓塞を予防します
G R Cousins1, G S Friedrichs, Y Sudo
1Department of Pharmacology, University of Michigan Medical School, Ann Arbor 48109-0632, USA.
Circulation
|October 1, 1996
まとめ
経口直接トロンビン阻害剤CVS-1123は,動脈損傷後の犬における冠動脈栓塞を効果的に予防しました. この研究は,CVS-1123を臨床使用のための潜在的な抗血栓剤として強調しています.
科学分野:
- 心血管研究 循環器科の研究
- 薬理学 薬理学とは
- トロンボシス研究研究
背景:
- CVS-1123の経口有効性を調査しました. CVS-1123は,直接のトロビン抑制剤です.
- 動脈損傷後の閉塞性冠動脈栓塞を軽減するために,トロンビン抑制の潜在能力を評価した.
研究 の 目的:
- CVS-1123の経口投与が動脈栓塞を予防できるかどうかを判断する.
- 動脈壁の損傷の犬のモデルでCVS-1123の有効性を評価する.
主な方法:
- 意識のある犬は,動脈壁の損傷を誘発する前に,経口CVS-1123 (20 mg/kg) またはプラセボを投与された.
- 冠動脈の通路性は,怪我後の24時間間モニタリングされた.
- 薬剤の血濃度およびex vivo血小板凝集を測定した.
主要な成果:
- CVS-1123で治療された11匹の犬のうち8匹が冠動脈の通路性を維持した.
- プラセボで治療を受けた10匹の犬全員が閉塞性動脈血栓を発症した.
- CVS-1123は血小板の集積を阻害し,活性化された部分性血栓プラスティンの時間を延長しました.
結論:
- 口服CVS-1123は,実験的な動脈損傷モデルにおいて,血栓形成を効果的に減少させました.
- CVS-1123のようなトロンビン特異性阻害剤は,ヘパリンに代替品を提供することがあります.
- CVS-1123は,長期の抗凝固療法において有望であることが示されています.
関連する概念動画
01:24Antiarrhythmic Drugs: Class II Agents as β-Adrenergic Blockers
Adrenergic stimulation generally impacts cardiac rate and rhythm. Specifically, stimulation of the β-adrenoceptors triggers an increase in intracellular calcium ion influx and pacemaker currents, which may cause arrhythmias. Catecholamines like adrenaline also demonstrate β2-adrenoceptor-mediated hypokalemia, impacting cardiac action potential and disrupting the normal cardiac rhythm. Class II antiarrhythmic drugs are β-adrenoceptor antagonists or β-blockers, which indirectly block calcium...
01:20Antiarrhythmic Drugs: Class IV Agents as Calcium Channel Blockers
Class IV antiarrhythmic drugs, such as verapamil and diltiazem, block calcium channels. They primarily affect the heart, slowing the conduction in calcium-dependent tissues like the SA and AV nodes. These drugs manage reentrant supraventricular tachycardia (SVT) and reduce ventricular rate in atrial flutter/fibrillation.
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
Verapamil, a calcium channel blocker, inhibits calcium movement across myocardial cell membranes and vascular smooth muscle. This results in the dilation of coronary and...
01:20Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors
Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
01:16Antianginal Drugs: Nitrates and β-Blockers
In cardiovascular health, antianginal drugs combat angina pectoris — a condition marked by chest pain owing to diminished blood flow to the heart.
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
Organic nitrates, such as nitroglycerin, play a pivotal role. Once metabolized, they liberate nitric oxide, a molecular marvel. Nitric oxide triggers guanylyl cyclase and augments cGMP production. This biochemical cascade orchestrates the relaxation of vascular smooth muscles, ushering in vasodilation and enhancing coronary blood flow. Administered...
01:25Antianginal Drugs: Calcium Channel Blockers and Ranolazine
Angina pectoris, a primary symptom of ischemic heart disease, requires careful pharmacological interventions. In this context, calcium channel blockers (CCBs) and ranolazine have emerged as crucial pharmacotherapeutic agents, providing deep insights into the complexities of angina management.
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
CCBs, a diverse class that includes dihydropyridines (nifedipine) and diphenylalkylamines (verapamil and diltiazem), exert their effect by blocking calcium channels in cardiac and smooth muscle cells. This...
01:25Cardiopulmonary Resuscitation IV: Pharmacological Management
Pharmacologic intervention is crucial in treating cardiac arrest patients during ACLS or Advanced Cardiovascular Life Support. The ACLS algorithms guide the administration of specific drugs based on the patient's cardiac arrest rhythm, which includes pulseless ventricular tachycardia (VT), ventricular fibrillation (VF), asystole, and pulseless electrical activity (PEA).EpinephrineIndication: Epinephrine is the first-line drug for all cardiac arrest rhythms.Mechanism of Action: Epinephrine...